Bolt Biotherapeutics to Participate in Upcoming September Conferences

Rhea-AI Summary

Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies, has announced its participation in two major conferences this September. The company will be featured in:

1. A fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 7:00 a.m. EDT.

2. A company presentation at the H.C. Wainwright 26th Annual Global Investment Conference, available from September 9, 2024, at 7:00 a.m. EDT.

Both presentations will be accessible via webcast on Bolt's website, with replays available for 30 days after each event. This participation demonstrates Bolt's commitment to engaging with investors and showcasing its progress in the competitive field of cancer immunotherapy.

REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September:

• Morgan Stanley 22^nd Annual Global Healthcare Conference
  Fireside chat on Friday, Sept. 6, at 7:00 a.m. EDT (4:00 a.m. PDT)
  
• H.C. Wainwright 26^th Annual Global Investment Conference
  Company presentation available on Monday, Sept. 9, at 7:00am EDT (4:00 a.m. PDT)

A webcast of the presentations will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.

About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.

Investor Relations and Media Contact:
Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com

FAQ

When is Bolt Biotherapeutics (BOLT) participating in the Morgan Stanley Global Healthcare Conference?

Bolt Biotherapeutics (BOLT) is participating in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Friday, September 6, 2024, at 7:00 a.m. EDT (4:00 a.m. PDT).

What conference is BOLT presenting at on September 9, 2024?

BOLT is presenting at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, with the company presentation available from 7:00 a.m. EDT (4:00 a.m. PDT).

How can investors access Bolt Biotherapeutics' (BOLT) conference presentations?

Investors can access BOLT's conference presentations via webcast on the Events and Presentations page of Bolt's website at www.boltbio.com. Archived replays will be available for 30 days following each event.

What type of company is Bolt Biotherapeutics (BOLT)?

Bolt Biotherapeutics (BOLT) is a clinical-stage biopharmaceutical company that develops novel immunotherapies for the treatment of cancer.